
Non-small cell lung cancer program in Pharmaceutical Benefits Scheme (PBS) 012-18051128

-   Background
-   Process
-   Resources

[Expand/Collapse all sections]Expand all

This document outlines details of the Pharmaceutical Benefits Scheme
(PBS) subsidised crizotinib, and entrectinib for patients with Stage
IIIB or Stage IV non-small cell lung cancer (NSCLC).

Non-small cell lung cancer and listing dates

Non-small cell lung cancer (NSCLC) is 1 of 2 major types of lung cancer
that can affect smokers and non-smokers.

Listing dates are as follows:

-   crizotinib – listed 1 July 2015
-   entrectinib – listed 1 August 2020

See Written Authority Required Drugs for further information.

Enquiries

Transfer enquiries about prescription arrangements to the PBS Complex
Drugs Programs team, and choose the team relevant to the condition being
treated.

The Resources page contains links to application forms, contact details,
item codes, restriction, the Pharmaceutical Benefits Scheme (PBS) and
the Services Australia website.

Related links

Manage work items in Processing and National Demand Allocation (PaNDA)

Online Pharmaceutical Benefits Scheme (PBS) Authorities System (OPA)

Process telephone authority approval application

Processing Written Authority Required Listings

Written Authority Required Drugs

                                   

-   Services Australia ABN 90 794 605 008 
